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Abstract
Increased arterial stiffness and wave reflection have been identified as cardiovascular disease risk
factors. In light of significant sex differences and the moderate heritability of vascular function
measures, we hypothesized that variation in the genes coding for estrogen receptors alpha (ESR1)
and beta (ESR2) and aromatase (CYP19A1) is associated with aortic stiffness and pressure wave
reflection as measured by noninvasive arterial tonometry. 1261 unrelated Framingham Offspring
Study participants who attended the 7th examination cycle (mean age 62±10 years, 52% women) and
had arterial tonometry and genotyping data were included in the study. ANCOVA was used to assess
the association of polymorphisms with forward wave amplitude, augmented pressure, augmentation
index, carotid-femoral pulse wave velocity, and mean arterial pressure with adjustment for potential
confounders. In the sex-pooled analysis, those homozygous for the minor allele at any of four
ESR1 variants that were in strong linkage disequilibrium ((TA)n, rs2077647, rs2234693 and
rs9340799) had on average 18% higher augmented pressure and 16% greater augmentation index
compared to carriers of one or two major alleles (p=0.0002–0.01). A similar magnitude of association
was detected in those homozygous for the common allele at two ESR2 SNPs (p=0.007–0.02). Our
results are consistent with the hypothesis that variation in ESR1 and ESR2, but not CYP19A1, is
associated with increased wave reflection, which may contribute to previously demonstrated
associations between these variants and adverse clinical events. Our findings will need to be
replicated in additional cohorts.
Keywords
arterial stiffness; tonometry; estrogen receptor; polymorphism
Correspondent Author: Inga Peter, PhD, Associate Professor of Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, New
York, NY 10029, USA, Tel: (212)-659-8566, Fax: (212)-659-5657, Email: inga.peter@mssm.edu.
NIH Public Access
Author Manuscript
J Hum Hypertens. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
J Hum Hypertens. 2009 October ; 23(10): 636–644. doi:10.1038/jhh.2009.1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
Increased arterial stiffness and wave reflection play important roles in cardiovascular
physiology. Aortic stiffness, estimated by measurement of carotid-femoral pulse wave velocity
(CFPWV), has been identified as a cardiovascular disease (CVD) risk factor in 3 large,
independent, community-based cohorts.1–3 Some studies show that CFPWV and pulse
pressure are lower in women than men prior to 60 years of age, but increase rapidly in women
thereafter, resulting in comparable CFPWV and higher pulse pressure in older women.
Similarly, the incidence of CVD is low in premenopausal women as compared to their male
peers, but increases sharply after menopause.4 In light of the associations between aortic
stiffness and events, the disproportionate increase in aortic stiffness in older women may
contribute to the higher incidence of CVD in women after the menopause. In contrast, measures
of wave reflection, such as augmented pressure or augmentation index, are increased in women
as compared to men at all ages, with a maximal difference just prior to menopause and a trend
for values in women and men to converge after 60 years of age. Increased wave reflection in
women has been attributed to shorter stature, but differences persist after adjusting for
height5 and when women and men are matched for height,6 suggesting intrinsic sex differences
in structure or function of the arterial system.
Estrogen is known to play an important role in endothelial function in both men and women.
Premature ovarian failure has been shown to be associated with significant endothelial
dysfunction.7, 8 In postmenopausal women, estrogen therapy has been shown to enhance
endothelium-dependent vasodilation and reduce arterial stiffness in some studies.9, 10
Estrogen is known to have short and long-term effects on the vasculature (reviewed in 11). The
rapid vasodilatory effects of estrogen are produced by estrogen-stimulated increases in
endothelial cell nitric oxide (NO) synthase activity which regulates vascular tone,12 suppresses
smooth muscle proliferation13 and inhibits platelet adhesion and aggregation14. Longer-term
effects are mediated through estrogen-activated transcription factors, estrogen receptor (ER)
α, (encoded by the ESR1 gene) and ERβ (encoded by the ESR2 gene), which are found in
vascular endothelial and smooth muscle cells in both men and women.15, 16
Recently, genetic variations of the major proteins involved in steroid hormone conversion and
receptor function have been shown to be associated with the increased risk of myocardial
infarction17 and coronary artery disease,18–20 elevated blood pressure,21 altered lipoprotein
particles concentrations,22, 23 adiposity, 24 and left ventricular mass,25–27 attracting increased
attention to genes implicated in estrogen metabolism. Also, variation in the gene (CYP19A1)
encoding the enzyme aromatase, which catalyzes the conversions of testosterone to estradiol
and defines the estradiol/testosterone ratio, has been found to be associated with blood
pressure21 and abdominal obesity.28 However, despite these and other studies, potential
molecular mechanisms linking estrogen-related genes with CVD risk remain incompletely
understood.
Given significant sex differences in vascular stiffness and moderate heritability of key arterial
pressure waveform phenotypes,29, 30 we hypothesized that variation in ESR1, ESR2, and
CYP19A1 are associated with aortic stiffness, pressure wave reflection and vasodilator function
as measured by noninvasive tonometry and brachial ultrasound in the Framingham Offspring
Study.
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Material and Methods
Study cohort
The study sample was derived from unrelated participants in the longitudinal community-based
Framingham Offspring cohort of European descent and is described in detail elsewhere.31
Eligible participants consented to genetic analysis and attended the 7th examination cycle
(1998–2001), during which they underwent routine medical history, physical examination,
tonometry measures and brachial ultrasound. Unrelated participants (N=3539) were selected
based on family structure alone without regard to any phenotypic traits and were excluded from
the present analysis if they did not have tonometry measures or brachial ultrasound data
(N=1508) or had missing genotype data (N=770). The final sample included 1261 individuals:
604 men and 657 women.
All participants gave written informed consent including consent for DNA analyses. The FHS
protocol was approved by the Boston University Medical Center Institutional Review Board.
Noninvasive Tonometry Measures
Participants were studied in the supine position after several minutes of rest as described
previously.5 Arterial tonometry, with simultaneous ECG, was obtained from the brachial,
radial, femoral, and carotid arteries. Transit distances were assessed by body surface
measurements from the suprasternal notch to each pulse recording site. Tonometry waveforms
were analyzed as described previously.5. CFPWV was calculated from tonometry waveforms
and body surface measurements. The CFPWV distance was measured with a fiberglass tape
measure. The central forward wave amplitude was defined as the difference between pressure
at the waveform foot and pressure at the first systolic inflection point or peak of the carotid
pressure waveform. Augmented pressure was defined as the difference between central systolic
pressure and pressure at the forward wave peak. Augmentation index (AI) was calculated as
previously described.32 Systolic ejection period was defined as the time interval from the
carotid pressure waveform foot to the dicrotic notch.
Brachial Artery Measures
Brachial artery diameter and mean flow velocity at baseline and 1-minute after reactive
hyperemia, induced by 5-mintue forearm cuff occlusion, were assessed as previously
described,33, 34 by using a Toshiba SSH-140A ultrasound system and commercially available
software (Brachial Tools, version 3.2.3). Mean Doppler flow velocity was analyzed using a
semi-automated signal averaging approach (Cardiovascular Engineering, Inc.).
Single Nucleotide Polymorphism (SNP) Selection and Genotyping
To investigate pathophysiologic connection between arterial stiffness and cardiovascular
disease, we selected a priori SNPs in ESR1, ESR2, and CYP19A1 found to be associated with
cardiovascular risk phenotypes in the Framingham Offspring cohort by our previous studies.
17, 21–24, 26, 27 Genomic DNA was extracted from peripheral blood leukocytes using standard
methods. Genotyping for the individual SNPs in ESR1 (rs2077647, rs2234693, rs9340799,
and rs1801132), ESR2 (rs944460, rs1256059, rs1256034, and rs1256031), and CYP19A1
(rs700518, rs726547), was performed as described previously.21, 35 ESR1 (TA)n, ESR1
(CA)n, ESR2 (CA)n, and CYP19A1 (TTTA)n repeat polymorphisms were genotyped using
restriction fragment length analyses.36
Statistical Analysis
Observed genotype frequencies were compared with those expected under Hardy–Weinberg
equilibrium (HWE) using a χ2 test. Given multiple alleles observed for the repeat
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polymorphisms and their bimodal distribution, the genotype carrier status for each variant was
coded using the median number of repeat sequence base pairs as a cutoff. Specifically, genotype
LL was assigned if both alleles contained at least the median number of base pairs (≥176 for
ESR1 (TA)n; ≥277 for ESR1 (CA)n; ≥162 for ESR2 (CA)n, and ≥298 for CYP19A1 (TTTA)n);
SS was assigned if both alleles were ‘short’ (<176 for ESR1 (TA)n; <277 for ESR1 (CA)n; <162
for ESR2 (CA)n, and <298 for CYP19A1 (TTTA)n), and LS if one allele was ‘long’ and another
one was ‘short’.
We used a general model of inheritance and sex-pooled analyses to assess relations between
estrogen pathway genotypes and vascular phenotypes. Multivariable linear regression analyses
were carried out to assess genetic associations with forward wave amplitude, augmented
pressure, AI, and CFPWV. All analyses were adjusted for age, sex, heart rate, body mass index
(or weight and height for augmented pressure and AI), mean arterial pressure (for CFPWV),
total/high-density lipoprotein cholesterol ratio, triglycerides, fasting glucose, diabetes,
smoking within past 6 hours, prevalent cardiovascular disease, hormone replacement therapy
(in women), hypertension medication, and lipid-lowering medication. To account for sex-
specific differences previously reported in relations between estrogen pathway genotypes and
cardiovascular phenotypes in the Framingham sample,17, 22, 23, 27 interactions between sex
and genotype were assessed by the addition of a multiplicative term to the fully adjusted model.
Forearm vascular resistance was skewed and was natural log transformed to normalize the
variance.
Pairwise linkage disequilibrium (LD) was evaluated by Lewontin’s D′.37 Haplotypes were
inferred by using the expectation maximization algorithm.38 To account for allelic interaction,
haplotypes were used as predictors in the regression models along with the above covariates.
The nominal threshold for statistical significance of all analyses was set at 0.05 and was not
adjusted for multiple testing. All analyses were performed using SAS/STAT and SAS/Genetics
software version 9.1 (SAS Institute, Inc., Cary, North Carolina, USA).
Results
The clinical characteristics of the unrelated Framingham Offspring Study participants included
in this analysis are shown in Table 1. Vascular phenotypes are summarized in Table 2 and
characteristics of the genotyped polymorphisms are summarized in Table 3.
ESR1 association analysis
In the sex-pooled analysis, those homozygous for the minor alleles for ESR1 (TA)n,
rs2077647, rs2234693, and rs9340799 had higher augmented pressure and AI (Table 4) as
compared to carriers of one or two major alleles (recessive model, p range 0.0001–0.04).
Associations were more pronounced in individuals not receiving antihypertensive treatment
and in women, who had particularly higher augmented pressure and AI (data not shown). No
significant sex-genotype and treatment-genotype interaction was detected. Also, we observed
a modest association of several of the ESR1 variants on heart rate, which was lower in the
groups with higher AI (Online Supplement Table I). In our sample, lower heart rate
significantly correlated with higher augmented pressure and AI (r=−0.25 and −0.28,
respectively; p<0.0001).
Strong LD detected between four of the six ESR1 markers (pairwise D′ ranges between 0.82
and 0.99, Online Supplement Figure) resulted in three common haplotypes, H5: (TA)n [L]-
rs2077647[C] - rs2234693[C] rs9340799[G] with the frequency of 32.7%, H6: (TA)n [L]-
rs2077647[C] - rs2234693[C] rs9340799[A] with the frequency of 6.9% and H12: (TA)n [S]-
rs2077647[T] - rs2234693[T] rs9340799[A] with the frequency of 45.8%. However, the data
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indicate that haplotypes did not explain larger proportions of variation in augmented pressure
and AI than individual SNPs.
No association was detected between ESR1 polymorphisms and forward pressure wave
amplitude or CFPWV. Both of these measures showed weak to moderate correlations with
augmented pressure (r=0.18, p<0.0001 and r=−0.08, p=0.009, respectively), AI (r=−0.14,
p<0.0001 and r=−0.08, p=0.005, respectively) and the heart rate (r=0.04, p=0.13 and r=0.20,
p<0.0001, respectively). In addition, no associations were detected between ESR1
polymorphisms and any of the brachial flow measures (p>0.05).
ESR2 association analysis
Similar to the ESR1 analysis, in the sex-pooled sample, ESR2 rs944460 and rs1256034
genotypes were related to augmented pressure and AI (Table 5). Those homozygous for the
major allele of ESR2 rs944460 and rs1256034, had higher augmented pressure and AI than
carriers of the minor allele.
Strong LD was detected between the two pairs of ESR2 SNPs (Table 5). However, the
correlation between them, or r2, was small due to low minor allele frequency for rs944460 and
rs1256034 (Online Supplement Figure), which resulted in a large number of rare haplotypes.
No association was detected between ESR2 polymorphisms and forward pressure wave or
CFPWV. In addition, no associations were detected between ESR2 polymorphisms and any of
the brachial flow measures (p>0.05).
CYP19A1 association analysis
No association was detected between the CYP19A1 SNPs (Online Supplement Figure) and
studied vascular measures (Online Supplement Table II) (p>0.05).
Interaction effects
On the basis of significant interactive effects of ESR1 rs2234693 and smoking status on
lipoprotein profile detected in a previous study,22 we tested the hypothesis that ESR1
rs2234693 interacts with smoking status. Regardless of genotype, in the multivariable-adjusted
model smokers had higher augmented pressure and greater AI than non-smokers (10.4±5.0 vs.
8.6±4.8 mm Hg; p=0.01 and 20.0±7.1 vs. 15.8±6.4%; p<0.0001, respectively). Furthermore,
homozygosity for the ESR1 rs2234693 C allele had an enhanced association with augmented
pressure and AI in smokers (p=0.04 and p=0.02, respectively, for the genotype-smoking
interaction term) (Figure).
Discussion
We evaluated relations between genetic variants in the ESR1, ESR2 and CYP19A1 genes and
key arterial function phenotypes assessed by tonometry and brachial reactivity in unrelated
individuals from the Framingham Heart Study Offspring cohort. In models that adjusted for a
number of potential confounders, rare alleles of the closely related ESR1 polymorphisms and
common alleles of the linked ESR2 polymorphisms were associated with higher augmented
pressure and greater AI. In sex-pooled analyses, those homozygous for the minor allele at any
one of the four ESR1 SNPs, which were all in strong LD, had on average 17% higher augmented
pressure and 15% greater AI compared to carriers of one or two major alleles. A similar
direction and magnitude of association was detected in those homozygous for the common
allele at two strongly linked ESR2 SNPs. No association was found between the CYP19A1
SNPs and vascular measures. These analyses were prompted by significant associations
detected between ESR1 and ESR2 gene polymorphisms and a number of cardiovascular
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phenotypes in the Framingham Heart Study, including myocardial infarction,17 elevated blood
pressure,21 altered lipoprotein profile,22, 23 adiposity,24 and changes in left ventricular
structure.26, 27 The present findings of an association between common variants in estrogen
pathway genes and measures of wave reflection suggest that abnormal pulsatile load may be
involved in the pathogenesis of the foregoing adverse clinical phenotypes.
Reported associations were seen in four closely linked ESR1 SNPs, two of which may have
direct relevance to vascular function. Specifically, the ESR1 TA polymorphism is located in
the regulatory region of the gene ~1174 base pairs upstream of the first exon39 between
promoters B and C.40 The long allele has been associated with worse cardiovascular risk profile
in previous reports. Namely, compared with short allele carriers, the TA L polymorphism has
been linked with more severely diseased coronary arteries,19, 41 and a higher risk of myocardial
infarction.41 In the present study, ESR1 (TA)n LL homozygotes had significantly lower heart
rate and higher augmented pressure amplitude and AI compared to carriers of one or two S
alleles. Although the exact mechanism whereby the ESR1 TA repeat polymorphism may affect
the vasculature is unclear, it is possible that this variant alters ESR1 transcript length or RNA
splicing causing significant heterogeneity in ERα mRNA transcripts. It has been shown
previously that alternative splicing may result in variants with deletions of exons encoding
regions of the hormone-binding domain with truncated forms of ERα discovered in many
tissues including vascular endothelium and showing altered ligand-activation properties
(reviewed in 42).
Higher augmented pressure and AI were also detected with the C allele of another variant,
ESR1 rs2234693, which is known to produce a functional myb binding site that might amplify
ERα transcription or produce ERα isoforms with properties that differ from those of the full-
length gene product.43
ERϐ is required for normal vasodilatation and blood pressure in both male and female mice,
with loss of ERϐ causing substantial hypertension, particularly in males.44 We found
associations of higher augmented pressure and AI with common variants in the two linked
intronic SNPs that have no known functional effect on the receptor. These variants may regulate
RNA splicing or transcription causing differences in expression levels, relative abundance of
multiple ESR2 splice forms, or ligand binding affinity. However, given an unusually large
distance between the ESR2 SNPs that are in LD (>30,000 base-pairs), it is possible that the
observed associations may be due to the existence of as yet undetected coding variants located
between and in LD with the genotyped SNPs.
We also observed a modest effect of several of the ESR1 variants on heart rate. In our sample,
lower heart rate significantly correlated with higher augmented pressure and AI and could
contribute to the increase in AI. Noteworthy, it has been shown that AI shares 4.6% common
genetic component with heart rate.29 However, it is important to emphasize that our models
included an adjustment for systolic ejection period or heart rate.
In the present study, we found no association of ER genotype carrier status with forward
pressure wave amplitude or CFPWV. Both of these measures showed weak to moderate
correlations with augmented pressure and heart rate. However, in an earlier study, Japanese
women who were carriers of ESR1 rs2234693 CC were shown to have lower brachial-ankle
pulse wave velocity, which is a measure of the spatially averaged properties of the aorta and
peripheral arteries.46 Interestingly, female carriers of the common ESR1 rs2234693 C allele
from the Framingham Offspring cohort had a larger average low-density lipoprotein (LDL)
particle size and a lower concentration of small LDL particles, which is a protective lipid
profile.23 Taken together, these data suggest that brachial-ankle pulse wave velocity may be
modified through favorable estrogen-induced changes in lipoprotein properties in carriers of
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the minor allele. In contrast, the same genotypes may increase arterial wave reflection because
of direct effects of estrogen on vascular tone in the periphery.
In the present study we detected effect modification by smoking status. That is, among smokers,
those who were homozygous for the ESR1 rs2234693 C allele had a 40% higher augmented
pressure and 33% greater AI than carriers of one or two major alleles (Figure). Importantly,
significant ESR1 rs2234693 - smoking status interaction in this cohort has been found with
lipoprotein fraction concentrations.22 Among smokers, female carriers of ESR1 rs2234693
TT genotype had higher small LDL particle concentrations and lower LDL particle sizes than
non-carriers, while no such association was detected in non-smokers. It has been shown that
acute tobacco use provokes endothelial dysfunction and abolishes the protection of circulating
estrogen.47 It will require further studies to determine how variation in ESR1 interacts with
cigarette smoking.
There are several potential limitations of our study. The design of this study, like any other
genetic association studies, does not allow drawing definitive conclusion about the exact
mechanisms that may lead to increased wave reflection. Moreover, the study cohort was
middle-aged to elderly and white of European descent, which may limit the generalizability of
our findings to younger individuals and other ethnic backgrounds. Also, we analyzed SNPs
that have been previously implicated in cardiovascular phenotypes; thus, we may have missed
associations attributable to other polymorphisms not sufficiently linked to the SNPs that we
evaluated. In addition, no adjustment for multiple testing was carried out. A standard correction
for multiple hypothesis testing relies on the assumption that all statistical comparisons are
independent. In the case of ESR1, ESR2 and CYP19A1, most of the polymorphisms were in
strong LD with one another, and tonometry measures were correlated. Moreover, we tested a
priori hypotheses based on reported findings with regard to these gene variants; therefore
rigorous adherence to the correction for multiple testing may have increased Type II error. The
consistency and biological relevance of these associations should motivate further research to
verify and extend these findings. We acknowledge that our findings will need to be replicated
in other cohorts.
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Figure. Tonometry phenotypes by smoking status and the ESR1 rs2234693 genotype in the sex-
pooled sample
Gene*smoking interaction adjusted
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Table 1
Sample characteristics.
Variable Men (N=604) Women (N=657)
Age, years 62±10 62±9
Systolic blood pressure, mmHg 129±18 127±20
Diastolic blood pressure, mmHg 76±10 72±10
Heart rate, bpm 62±11 64±10
Body mass index, kg/m2 28.6±4.5 27.3±5.5
Total/high-density cholesterol, ratio 4.4±1.3 3.6±1.1
Triglycerides, mg/dL 141±104 128±74
Fasting glucose, mg/dL 109±28 101±25
Diabetes, % 15 9
Smoking within past 12 month, % 12 14
Smoking within past 6 hours, % 8 9
Prevalent cardiovascular disease, % 19 10
Postmenopausal women, % - 86
Hormone replacement therapy, % - 37
Hypertension, % 51 46
Hypertension medication, % 39 33
Lipid-lowering medication, % 25 18
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Table 2
Vascular phenotypes.
Variable Men (N=604) Women (N=657)
Tonometry variables (mean±SD)
 Forward pressure wave amplitude, mmHg 41±14 42±13
 Augmented pressure amplitude, mmHg 7±6 11±9
 Carotid-femoral pulse wave velocity, m/s 11±4 10±3
 Augmentation index, % 13±10 20±12
 Systolic ejection period, ms 308±29 319±27
Brachial reactivity variables (median (Q1–Q3))
 Baseline Diameter (mm) 4.90 (4.51–5.33) 3.65 (3.31–4.01)
 Flow-Mediated Dilation (%) 1.8 (0.5–3.6) 2.8 (1.1–5.1)
 Baseline Volume Flow (ml/s) 1.4 (0.9–2.0) 0.7 (0.5–1.0)
 Hyperemic Flow Velocity (cm/s) 45 (30–61) 52 (36–70)
Q1, indicates first quartile; Q3 indicates third quartile.
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Table 6
Summary
What is known about this topic:
• Aortic stiffness has been identified as a cardiovascular disease risk factor in three large, independent, community-based cohorts.1–3
• Estrogen is known to play an important role in endothelial function in both men and women.
• Genetic variations of the major proteins involved in estrogen conversion and receptor function have been shown to be associated with the
increased risk of myocardial infarction17 and coronary artery disease,18–20 elevated blood pressure,21 altered lipoprotein particles
concentrations,22, 23 adiposity, 24 and left ventricular mass.25–27
What this Study adds:
• This 1261 unrelated Framingham Offspring Study participants shows that variation in ESR1 and ESR2, but not CYP19A1 may predispose
to excess pressure wave reflection, which may contribute to morbidity from several complex diseases.
• Finding genes associated with excess wave reflection may help elucidate hemodynamic mechanisms of disease pathogenesis and enhance
our ability to favorably manipulate vascular responses in genetically susceptible individuals before clinical manifestations occur.
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